S. 79 118th Congress
Interagency Patent Coordination and Improvement Act of 2023
Latest action, Mar 1, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
5 cosponsors
Sponsored by Richard J. Durbin (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
3 D · 2 R
- Democrat
- Republican
- Independent
Referred to: Senate: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMGEN
THE NICKLES GROUP, LLC
8 reports
8 reports
AMGEN USA INC.
MARSHALL & POPP, LLC
8 reports
8 reports
FRESENIUS KABI USA LLC
WEST FRONT STRATEGIES LLC
8 reports
GENENTECH, INC.
MARSHALL & POPP, LLC
8 reports
8 reports
8 reports
8 reports
PFIZER, INC.
MARSHALL & POPP, LLC
8 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
MARSHALL & POPP, LLC
8 reports
All 25 of 37 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 8 | $24.8M | Q1 2023 | Q3 2024 | yes | |
| AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) | 8 | $30K | Q1 2023 | Q3 2024 | yes | |
| AMGEN | THE NICKLES GROUP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| AMGEN INC | 8 | $22.9M | Q1 2023 | Q3 2024 | yes | |
| AMGEN USA INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 8 | $1.8M | Q1 2023 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 8 | $15.7M | Q1 2023 | Q3 2024 | yes | |
| FRESENIUS KABI USA LLC | WEST FRONT STRATEGIES LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| GENENTECH, INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| JOHNSON & JOHNSON SERVICES INC | 8 | $14.6M | Q1 2023 | Q3 2024 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 8 | $551K | Q1 2023 | Q3 2024 | yes | |
| NOVARTIS | 8 | $11.7M | Q1 2023 | Q3 2024 | yes | |
| PFIZER, INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 8 | $58.1M | Q1 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| SANOFI U.S. SERVICES, INC. | MARSHALL & POPP, LLC | 8 | $480K | Q1 2023 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.9M | Q1 2023 | Q3 2024 | yes | |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 7 | $380K | Q4 2023 | Q3 2024 | yes |
| VIATRIS INC | WEST FRONT STRATEGIES LLC | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| AARP | 5 | $22.4M | Q1 2023 | Q2 2024 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 5 | $120K | Q4 2023 | Q3 2024 | yes |
| CHAMBER OF COMMERCE OF THE U.S.A. | 5 | $93.5M | Q4 2023 | Q3 2024 | yes | |
| JUSTICE ACTION NETWORK | PENN AVENUE PARTNERS | 5 | $100K | Q1 2023 | Q1 2024 | yes |
| PUBLIC CITIZEN | 5 | $371K | Q1 2023 | Q4 2024 | yes | |
| AMERICAN CIVIL LIBERTIES UNION | BRIMLEY GROUP INC. | 3 | $0 | Q1 2023 | Q3 2023 | yes |